Source: Therma Bright.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Therma Bright (THRM) has submitted its Health Canada application for its AcuVid COVID-19 Rapid Antigen Saliva Test for Point-of-Care (POC)
  • The HC application includes all the updated data from the company’s U.S. Food and Drug Administration’s Emergency Use Authorization (EUA) application
  • Prior to this news, the company was busy clarifying questions on the EUA application to meet the application requirements better
  • It reworked follow-up answers and reformatted some data
  • Therma Bright Inc. (THRM) is in the red, down 3.23 per cent, trading at C$0.15 at market close

Therma Bright (THRM) has submitted a Health Canada (HC) application for the smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test.

The HC application for Point-of-Care Use (PoC) includes all the updated data from the company’s U.S. Food and Drug Administration’s Emergency Use Authorization (EUA) application.

“We’re excited with our AcuVid Health Canada application and the prospect of approval for our unique COVID-19 rapid antigen saliva test for point-of-care (PoC),” shared Rob Fia, CEO of Therma Bright.

“[…] our team has begun preparing other regulatory applications where we believe our AcuVid™ COVID-19 Rapid Antigen Saliva Test will be in high demand this fall when countries from around the globe expect a resurgence of Covid-19,” added Fia.

Before this news, the company was busy clarifying questions on the EUA application to better meet the requirements.

The developer of the smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test and other progressive medical device technologies, Therma Bright, has recently reworked follow-up answers and reformatted data.

While the company is not making any implied claims that its test product can eliminate or cure COVID-19 or the SARS-CoV-2 virus, Therma Bright thinks its product will be in demand later this year.

Therma Bright, a developer of the smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test, is a medical diagnostic and device technology company focused on quality and innovative solutions in the medical and healthcare field.

Therma Bright Inc. (THRM) is in the red, down 3.23 per cent, trading at C$0.15 at market close.

More From The Market Herald

" Satellos Bioscience (TSXV:MSCL) changing the way we think of degenerative muscle diseases

Satellos Bioscience (MSCL) has filed a patent application with the US Patent and Trademark Office.

" NervGen Pharma (TSXV:NGEN) announces US$15M private placement

NervGen Pharma (NGEN) has announced a non-brokered private placement for gross proceeds of US$15,225,000.

" Feeding our plant-based future

One of the fastest-growing segments today is the plant-based industry, as the push towards cleaner lifestyles, eating habits, and sustainable living choices fuel

" Salona Global (TSXV:SGMD) expands product distribution

Salona Global (SGMD) has signed an agreement to distribute the Hyperice suite of products and delivered 600 units of its newly launched Mio-Guard.